The global biomarker discovery outsourcing services market size is calculated at USD 17.42 billion in 2025 and is forecasted to reach around USD 86.74 billion by 2034, accelerating at a CAGR of 19.53% from 2025 to 2034. The North America market size surpassed USD 5.83 billion in 2024 and is expanding at a CAGR of 19.67% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Biomarker Discovery Outsourcing Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Biomarker Discovery Outsourcing Services Market, by Service Type
8.1.1. Biomarker Identification
8.1.1.1. Market Revenue and Forecast
8.1.2. Biomarker Validation & Qualification
8.1.2.1. Market Revenue and Forecast
8.1.3. Biomarker Assay Development
8.1.3.1. Market Revenue and Forecast
8.1.4. Clinical Biomarker Discovery
8.1.4.1. Market Revenue and Forecast
8.1.5. Companion Diagnostics Development
8.1.5.1. Market Revenue and Forecast
8.1.6. Bioinformatics & Data Analysis
8.1.6.1. Market Revenue and Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Forecast
9.1. Biomarker Discovery Outsourcing Services Market, by Technology Platform
9.1.1. Genomics
9.1.1.1. Market Revenue and Forecast
9.1.2. Proteomics
9.1.2.1. Market Revenue and Forecast
9.1.3. Transcriptomics
9.1.3.1. Market Revenue and Forecast
9.1.4. Metabolomics
9.1.4.1. Market Revenue and Forecast
9.1.5. Epigenomics
9.1.5.1. Market Revenue and Forecast
9.1.6. Lipidomics
9.1.6.1. Market Revenue and Forecast
9.1.7. Multi-omics Approaches
9.1.7.1. Market Revenue and Forecast
10.1. Biomarker Discovery Outsourcing Services Market, by Therapeutic Area
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Neurology
10.1.2.1. Market Revenue and Forecast
10.1.3. Cardiovascular Diseases
10.1.3.1. Market Revenue and Forecast
10.1.4. Immunology & Inflammatory Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Infectious Diseases
10.1.5.1. Market Revenue and Forecast
10.1.6. Metabolic Disorders
10.1.6.1. Market Revenue and Forecast
10.1.7. Others
10.1.7.1. Market Revenue and Forecast
11.1. Biomarker Discovery Outsourcing Services Market, by End User
11.1.1. Pharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Companies
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
11.1.4. Diagnostic Laboratories
11.1.4.1. Market Revenue and Forecast
11.1.5. CROs & Research Networks
11.1.5.1. Market Revenue and Forecast
12.1. Biomarker Discovery Outsourcing Services Market, by Biomarker Type
12.1.1. Prognostic Biomarkers
12.1.1.1. Market Revenue and Forecast
12.1.2. Diagnostic Biomarkers
12.1.2.1. Market Revenue and Forecast
12.1.3. Surrogate Biomarkers
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Service Type
13.1.2. Market Revenue and Forecast, by Technology Platform
13.1.3. Market Revenue and Forecast, by Therapeutic Area
13.1.4. Market Revenue and Forecast, by End User
13.1.5. Market Revenue and Forecast, by Biomarker Type
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Service Type
13.1.6.2. Market Revenue and Forecast, by Technology Platform
13.1.6.3. Market Revenue and Forecast, by Therapeutic Area
13.1.6.4. Market Revenue and Forecast, by End User
13.1.6.5. Market Revenue and Forecast, by Biomarker Type
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Service Type
13.1.7.2. Market Revenue and Forecast, by Technology Platform
13.1.7.3. Market Revenue and Forecast, by Therapeutic Area
13.1.7.4. Market Revenue and Forecast, by End User
13.1.7.5. Market Revenue and Forecast, by Biomarker Type
13.2. Europe
13.2.1. Market Revenue and Forecast, by Service Type
13.2.2. Market Revenue and Forecast, by Technology Platform
13.2.3. Market Revenue and Forecast, by Therapeutic Area
13.2.4. Market Revenue and Forecast, by End User
13.2.5. Market Revenue and Forecast, by Biomarker Type
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Service Type
13.2.6.2. Market Revenue and Forecast, by Technology Platform
13.2.6.3. Market Revenue and Forecast, by Therapeutic Area
13.2.7. Market Revenue and Forecast, by End User
13.2.8. Market Revenue and Forecast, by Biomarker Type
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Service Type
13.2.9.2. Market Revenue and Forecast, by Technology Platform
13.2.9.3. Market Revenue and Forecast, by Therapeutic Area
13.2.10. Market Revenue and Forecast, by End User
13.2.11. Market Revenue and Forecast, by Biomarker Type
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Service Type
13.2.12.2. Market Revenue and Forecast, by Technology Platform
13.2.12.3. Market Revenue and Forecast, by Therapeutic Area
13.2.12.4. Market Revenue and Forecast, by End User
13.2.13. Market Revenue and Forecast, by Biomarker Type
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Service Type
13.2.14.2. Market Revenue and Forecast, by Technology Platform
13.2.14.3. Market Revenue and Forecast, by Therapeutic Area
13.2.14.4. Market Revenue and Forecast, by End User
13.2.15. Market Revenue and Forecast, by Biomarker Type
13.3. APAC
13.3.1. Market Revenue and Forecast, by Service Type
13.3.2. Market Revenue and Forecast, by Technology Platform
13.3.3. Market Revenue and Forecast, by Therapeutic Area
13.3.4. Market Revenue and Forecast, by End User
13.3.5. Market Revenue and Forecast, by Biomarker Type
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Service Type
13.3.6.2. Market Revenue and Forecast, by Technology Platform
13.3.6.3. Market Revenue and Forecast, by Therapeutic Area
13.3.6.4. Market Revenue and Forecast, by End User
13.3.7. Market Revenue and Forecast, by Biomarker Type
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Service Type
13.3.8.2. Market Revenue and Forecast, by Technology Platform
13.3.8.3. Market Revenue and Forecast, by Therapeutic Area
13.3.8.4. Market Revenue and Forecast, by End User
13.3.9. Market Revenue and Forecast, by Biomarker Type
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Service Type
13.3.10.2. Market Revenue and Forecast, by Technology Platform
13.3.10.3. Market Revenue and Forecast, by Therapeutic Area
13.3.10.4. Market Revenue and Forecast, by End User
13.3.10.5. Market Revenue and Forecast, by Biomarker Type
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Service Type
13.3.11.2. Market Revenue and Forecast, by Technology Platform
13.3.11.3. Market Revenue and Forecast, by Therapeutic Area
13.3.11.4. Market Revenue and Forecast, by End User
13.3.11.5. Market Revenue and Forecast, by Biomarker Type
13.4. MEA
13.4.1. Market Revenue and Forecast, by Service Type
13.4.2. Market Revenue and Forecast, by Technology Platform
13.4.3. Market Revenue and Forecast, by Therapeutic Area
13.4.4. Market Revenue and Forecast, by End User
13.4.5. Market Revenue and Forecast, by Biomarker Type
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Service Type
13.4.6.2. Market Revenue and Forecast, by Technology Platform
13.4.6.3. Market Revenue and Forecast, by Therapeutic Area
13.4.6.4. Market Revenue and Forecast, by End User
13.4.7. Market Revenue and Forecast, by Biomarker Type
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Service Type
13.4.8.2. Market Revenue and Forecast, by Technology Platform
13.4.8.3. Market Revenue and Forecast, by Therapeutic Area
13.4.8.4. Market Revenue and Forecast, by End User
13.4.9. Market Revenue and Forecast, by Biomarker Type
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Service Type
13.4.10.2. Market Revenue and Forecast, by Technology Platform
13.4.10.3. Market Revenue and Forecast, by Therapeutic Area
13.4.10.4. Market Revenue and Forecast, by End User
13.4.10.5. Market Revenue and Forecast, by Biomarker Type
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Service Type
13.4.11.2. Market Revenue and Forecast, by Technology Platform
13.4.11.3. Market Revenue and Forecast, by Therapeutic Area
13.4.11.4. Market Revenue and Forecast, by End User
13.4.11.5. Market Revenue and Forecast, by Biomarker Type
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Service Type
13.5.2. Market Revenue and Forecast, by Technology Platform
13.5.3. Market Revenue and Forecast, by Therapeutic Area
13.5.4. Market Revenue and Forecast, by End User
13.5.5. Market Revenue and Forecast, by Biomarker Type
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Service Type
13.5.6.2. Market Revenue and Forecast, by Technology Platform
13.5.6.3. Market Revenue and Forecast, by Therapeutic Area
13.5.6.4. Market Revenue and Forecast, by End User
13.5.7. Market Revenue and Forecast, by Biomarker Type
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Service Type
13.5.8.2. Market Revenue and Forecast, by Technology Platform
13.5.8.3. Market Revenue and Forecast, by Therapeutic Area
13.5.8.4. Market Revenue and Forecast, by End User
13.5.8.5. Market Revenue and Forecast, by Biomarker Type
14.1. Eurofins Scientific
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Charles River Laboratories
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. ICON plc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Labcorp Drug Development
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. WuXi AppTec
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Syneos Health
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Q² Solutions (IQVIA & Quest Diagnostics JV)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Bio-Rad Laboratories
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. PPD Inc. (Thermo Fisher Scientific)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description